Novo Nordisk, the Danish pharmaceutical giant, has announced that CEO Lars Fruergaard Jørgensen will resign from his position. This decision comes as a mutual agreement between Jørgensen and the Novo Nordisk Foundation, aimed at addressing recent market challenges and shareholder concerns over dwindling company performance. Axios reported that the leadership change is seen as necessary to navigate the current turbulent market landscape.
Novo Nordisk is currently grappling with heightened competition in the weight-loss drug sector, a situation compounded by the success of Eli Lilly's Zepbound. Financial strains have deepened, with the company's share price plummeting more than 50% since mid-2024. As a result, Novo Nordisk has revised its sales and profit forecasts downward, reflecting decreased market share and profitability. Financial pressures are also growing due to impending Medicare drug price negotiations in the U.S., which could impact the pricing of their popular drugs.
Lars Fruergaard Jørgensen will remain temporarily to facilitate a smooth leadership transition. Meanwhile, the Novo Nordisk Foundation is strengthening its influence on the board, with chairman Lars Rebien Sørensen joining as an observer. Reuters has emphasized the significance of these changes as the company aims to regain its footing within the competitive pharmaceutical industry.